Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

Home > Urgent Suspected Cancer (USC) >

Patient Information & Safety-netting

Checked: 12-09-2023 by 3 Vicky Ryan Next Review: 12-09-2024

BNSSG Understanding Your Urgent Fast Track Referral Patient Information Leaflets

At time of referral please issue the BNSSG Understanding Your Urgent Fast Track Referral patient information leaflet.

This is available in English and the following 15 additional languages:

An Easy Read version of the leaflet is also available.

Urgent suspected cancer referral video

BNSSG ICB has worked with system partners to develop a video for patients referred on an urgent suspected cancer pathway. It is hoped this will improve patient experience and support patients to feel able and confident to attend their appointments.

The video is in seven languages and BSL; please consider adding this to the resources you give to patients when referring alongside the patient information leaflet.

Suspected Cancer - Safety-netting

Safety netting ensures patients undergoing investigations for cancer, or presenting with symptoms that may indicate serious disease, are followed up in a timely and appropriate manner.

The term 'safety netting' includes a wide range of actions and procedures. These may involve actions at an individual GP-patient consultation level and procedures implemented at a practice level.

Safety netting is particularly important for suspected cancer, where symptoms are common and often non-specific.

The following links provider further information and resources on this:

Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.